Genomic and Proteomic Network for Premature Birth Resea*

这项建议构成了犹他大学对NICHD基因组和蛋白质组的申请 早产儿出生研究网络。犹他大学拥有众多独特的优势， 使其成为网络的理想中心。其中包括：I.多中心的研究效率 合作研究：犹他大学母胎医学(MFM)分部已做出 在过去五年中，对15项多中心临床试验做出了重大贡献，是 NICHD/MFMU网络的领先招聘中心。超过12,000名犹他州患者 参加了最近完成的快速试验，在12名受试者中占了近32%- 中心审判。犹他大学也参与了斯蒂尔诞生合作研究网络 和全球妇女儿童健康研究网络。 早产：犹他州大学享有国际公认的早产中心地位 卓越的早产临床护理和研究。三、基因组学应用方面的专业知识 和蛋白质组学技术研究早产：母胎医学分会 发表了关于使用cDNA微阵列来鉴定具有劳工特异性表达的基因的情况 也报道了细胞因子基因多态性与自发性早产的关系。 不同民族的人口。我们最近还报告了使用蛋白质组学的经验 找出可能预测足月和早产的因素。四、生殖和医学遗传学： 犹他州独特的人口吸引了许多世界级的遗传学家来到这所大学。状态： ART分子和临床遗传能力将可用于该网络。五. 大学/社区协作：犹他州MFM专科医生有独特的临床和研究 跨越相互竞争的医疗保健系统的伙伴关系，并为患者提供普遍的 临床研究。六.经过验证的招生战略：研究基础设施目前已在 四个地区性三级护理中心已经并将继续允许犹他大学成为 在大型多中心试验的领先招募中心中。

This proposal constitutesthe University of Utah application for the NICHD Genomic and Proteomic Network for PrematureBirth Research. The University of Utah has numerousunique strengths that make it an ideal center for the network. These include: I. Research Productivity in Multicenter Collaborative Studies: The University of Utah Maternal-Fetal Medicine (MFM) Division has made substantial contributions to over 15 multicenter clinical trials during the past five years and is a leading recruitment center for the NICHD/MFMU Network. Over 12,000 Utah patients were enrolled in the recently completed FASTER trial, accounting for almost 32% of subjects in the 12- center trial. The University of Utah also participates in the Stillbirth Collaborative Research Network and the Global Network for Women's and Children'sHealth Research. II. Premature Birth: The Universityof Utah enjoys international recognitionas a center of excellence for clinical care and research on premature birth. III.Expertise in the Use of Genomic and Proteomic Techniques to Study Premature Birth: The Maternal-Fetal Medicine Divisionhas published on the use of cDNA microarray to identify genes with labor-specific expression within myometrium and has also reported on cytokine polymorphisms and spontaneous preterm birth in various ethnic populations. We have also recently reported experience with the use of proteomics to identify potentialpredictors of term and preterm birth. IV. Reproductive and Medical Genetics: Utah's distinctpopulation has attracted numerousworld-class geneticists to the University. State of the art molecularand clinical genetic capabilities will be made availableto the Network. V. University / Community Synergy: MFM specialistsin Utah have a unique clinical and research partnership that crosses competing health care systems and affords universalaccess to patients for clinical research. VI. Proven Enrollment Strategy: Research infrastructure is currentlyin place at four regional tertiary care centers that has and will continue to allow the University of Utah to be among the leading recruitment centers for large multicenter trials.